Predictive value of HIV-1 viral load on risk for opportunistic infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 30, Issue 2, 2002, Pages 154-158

  Swindells, Susan ^a   Evans, Scott ^a   Zackin, Robert ^a   Goldman, Mitchell ^a   Haubrich, Richard ^a   Filler, Scott G ^a   Balfour Jr , Henry H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Candidiasis; Opportunistic infection; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CANDIDIASIS; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS LOAD;

EID: 0036603064     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200206010-00003     Document Type: Article

References (30)

1. Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Changing patterns of mortality across Europe in patients infected with HIV-1
4. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
5. Determinants of virological response to antiretroviral therapy: Implications for long-term strategies
6. Outcome and predictors of failure highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
7. Human immunodeficiency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome
8. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
9. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
10. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
11. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
12. Prognostic value of plasma human immunodeficiency virus type I (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy
13. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS
14. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy
15. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter
16. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections
17. Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study
18. Discontinuation of PCP prophylaxis is safe in HIV-infected patients with immunologic recovery with HAART
19. Discontinuation of primary prophylaxis against PCP in HIV-infected adults treated with combination antiretroviral therapy
20. Discontinuation of PCP prophylaxis after start of HAART in HIV-1 infection
21. Discontinuation of PCP prophylaxis in HIV-1-infected patients treated with HAART
22. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count: A randomized, double-blind, placebo-controlled trial ACTG 362
23. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy
24. Lack of reactivation of CMV retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T-cells in response to HAART
25. Long-lasting remission of CMV retinitis without maintenance therapy in HIV-infected patients
26. Discontinuation of maintenance therapy in patients with quiescent CMV retinitis and elevated CD4 counts
27. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine
28. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
29. Strategies for optimizing adherence to highly active antiretroviral therapy: Lessons from research and clinical practice
30. Appropriate antimicrobial prescribing: Approaches that limit antibiotic resistance